6.85
前日終値:
$7.02
開ける:
$6.81
24時間の取引高:
13,228
Relative Volume:
0.26
時価総額:
$76.59M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.28%
1か月 パフォーマンス:
-0.72%
6か月 パフォーマンス:
-53.31%
1年 パフォーマンス:
+0.00%
Imagenebio Inc Stock (IMA) Company Profile
Compare IMA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
IMA
Imagenebio Inc
|
6.85 | 78.50M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | 再開されました | Wedbush | Underperform |
| 2025-10-24 | 開始されました | Leerink Partners | Outperform |
Imagenebio Inc (IMA) 最新ニュース
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com South Africa
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com
New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan
ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS
ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance
Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks
Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat
ImageneBio chief medical officer resigns, transition planned - MSN
ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks
ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com
ImageneBio assumed at Underperform from Neutral at Wedbush - MSN
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Rating of “Hold” by Brokerages - Defense World
ImageneBio Extends Agreement with Miragene Inc. - MSN
ImageneBio (IMA) price target decreased by 94.20% to 16.32 - MSN
ImageneBio (IMA) Stock Analysis Report | Financials & Insights - Benzinga
ImageneBio, Inc. (IMA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
ImageneBio, Inc. (IMA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Wedbush Comments on ImageneBio's Q4 Earnings (NASDAQ:IMA) - MarketBeat
ImageneBio (NASDAQ:IMA) Lowered to “Underperform” Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Rating Lowered to Underperform at Wedbush - Defense World
IMA interactive stock chart | ImageneBio, Inc. stock - Yahoo Finance Australia
Price performance - Yahoo Finance Australia
ImageneBio (NASDAQ:IMA) Downgraded to Underperform Rating by Wedbush - Defense World
ImageneBio (NASDAQ:IMA) Stock Rating Lowered by Wedbush - Defense World
Sell Recommendation for ImageneBio Due to Strategic Risks and Financial Challenges - TipRanks
Wedbush assumes coverage of ImageneBio stock with Underperform rating By Investing.com - Investing.com South Africa
ImageneBio (IMA) Receives Underperform Rating from Wedbush | IMA Stock News - GuruFocus
Wedbush assumes coverage of ImageneBio stock with Underperform rating - Investing.com India
Wedbush Assumes ImageneBio at Underperform With $2 Price Target vs. Prior Coverage at Underperform, $23 Price Target - marketscreener.com
ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year - MSN
ImageneBio Highlights IMG-007 in Corporate Update - TipRanks
ImageneBio, Inc Updates Corporate Presentation for Q4 2025 - TradingView
FY2025 EPS Estimates for ImageneBio Cut by Leerink Partnrs - Defense World
William Blair Estimates ImageneBio FY2025 Earnings - Defense World
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Yahoo Finance
ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to “Strong Sell” - Defense World
[424B3] ImageneBio, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
ImageneBio Reports Third Quarter 2025 Financial Results - TradingView
ImageneBio, Inc. SEC 10-Q Report - TradingView
ImageneBio Reports Third Quarter 2025 Financial Results and - GlobeNewswire
ImageneBio Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - The Manila Times
ImageneBio Expands Board, Appoints New Audit Chair - TipRanks
ImageneBio, Inc. Appoints Joseph P. Slattery to the Board, Effective November 1, 2025, and as Chair of the Audit Committee of the Board, Effective November 18, 2025 - MarketScreener
ImageneBio initiated with an Outperform at Leerink - MSN
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update - Defense World
Miragene Inc. Announces Extension of Key Service Agreement - MarketScreener
Imagenebio Inc (IMA) 財務データ
Imagenebio Inc (IMA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):